2 minute read
What It Is
Oxbryta (voxelotor) is a medication used to treat sickle cell disease [1] but recent reports have linked it to serious cardiovascular issues—including sudden cardiac death. [2] [3] Lawsuits are now being investigated for failure to warn about these risks.
What the Recall or Product Is
Approved in 2019, Oxbryta is manufactured by Global Blood Therapeutics [4] Though it increases hemoglobin, it may also pose serious heart risks—especially in children and young adults. [5]
What the Signature Injury Is and How It’s Hurting People
A key injury is liver toxicity. Oxbryta is processed in the liver and can cause elevations in liver enzymes, particularly: ALT (alanine aminotransferase) and AST (aspartate aminotransferase). Elevated levels of these enzymes can be a sign of inflammation or damage to liver cells.
Reported side effects include:
* Arrhythmias and heart palpitations
* Cardiac arrest
* Death during treatment
* Off-label use in younger patients without warning
These consequences are devastating for families and raise concerns about the drug’s safety profile.
Contact Us
If you or a loved one has experienced harm from taking Oxbryta medication, legal options may be available. Call Michael Brady Lynch Firm at 888-585-5970 or email brandon@mblynchfirm.com for a free consultation.
Date: June 03, 2025
Attorney and Editor-In-Chief: Brandon Salter
Editors: Connor Wright, Kali McElroy, and Madison Hurley
Citations:
[1] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-withdraws-sickle-cell-disease-treatment-all-markets-2024-09-25/
[3] https://pharmaceutical-journal.com/article/news/manufacturer-withdraws-treatment-for-sickle-cell-disease-following-concern-over-deaths
[4] https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-withdraws-sickle-cell-disease-treatment-all-markets-2024-09-25/
[5] https://www.biospace.com/business/pfizer-takes-sickle-cell-drug-oxbryta-off-global-market-cites-risk-of-death










